Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, Perez JL, Zerbini C, Dever ME, Jennings TW, Brandon DM, Cannon KD, Koren MJ, Denham DS, Berhe M, Fitz-Patrick D, Hammitt LL, Klein NP, Nell H, Keep G, Wang X, Koury K, Swanson KA, Cooper D, Lu C, Türeci Ö, Lagkadinou E, Tresnan DB, Dormitzer PR, Şahin U, Gruber WC, Jansen KU; C4591031 Clinical Trial Group.
Moreira ED Jr, et al.
N Engl J Med. 2022 May 19;386(20):1910-1921. doi: 10.1056/NEJMoa2200674. Epub 2022 Mar 23.
N Engl J Med. 2022.
PMID: 35320659
Free PMC article.
Clinical Trial.
We assessed vaccine safety and efficacy against Covid-19 starting 7 days after the third dose. ...CONCLUSIONS: A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with t …
We assessed vaccine safety and efficacy against Covid-19 starting 7 days after the third dose. ...CONCLUSIONS: A third dose of the BN …